Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA semaglutide injection kit, as supplied in the UK for weight management, contains a pre-filled pen, a package of disposable needles, and a patient information leaflet. The pen is not a vial-and-syringe set-up; it is self-contained and comes ready to use. That said, the kit alone does not make the treatment safe or legal — semaglutide is a prescription-only medicine, and a prescriber must assess whether it is right for you before anything is dispensed. This page explains what the kit contains, what the common myths around it get wrong, and what you should know before your first injection.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Many people assume that because Wegovy arrives pre-filled, the process is automatic, point, press, done. The pen does remove a lot of the complexity that older injectable medicines required, but technique still matters. Attaching the needle at an angle, forgetting to prime the pen on first use, or injecting too shallowly can all affect whether the full dose reaches the subcutaneous tissue it needs to reach. The step-by-step injection guide on this site covers those details properly.
The three recommended injection sites are the abdomen (at least a few centimetres from the navel), the front of the thigh, and the outer upper arm. Rotating between sites each week reduces local skin reactions and keeps tissue healthy over what is typically a multi-month course of treatment. Pressing the pen firmly against the skin before activating it helps ensure the needle travels to the right depth. These are small things, but getting them right is part of getting the most from treatment.
One practical note our prescribers raise often: the pen should come out of the fridge around 30 minutes before you use it. A cold injection is more likely to sting. Keep the pen in its box on the fridge door shelf rather than the back panel, it is easier to remember, and the temperature there is stable enough. The full explanation of injection discomfort is worth reading if that is a concern.
Wegovy is licensed in the UK by Novo Nordisk as a once-weekly subcutaneous injection. The pen itself is pre-filled with semaglutide solution and pre-set to a fixed dose, you do not measure anything. Needles are included but are a separate component: you attach one before injecting and remove it immediately afterwards to prevent air entering the pen and the dose drifting. Never store the pen with the needle attached.
What the kit does not include: a sharps disposal container. UK law requires used needles to be disposed of in an approved sharps bin, not in household recycling or general waste. If you do not already have one, a suitable 1-litre sharps container is available separately. Alcohol swabs for cleaning the injection site are also not always included, though some pharmacies supply them; they are genuinely useful for hygiene rather than just ritual. Everything else you need is in the box.
For a broader picture of how the semaglutide injection works (the pharmacology behind once-weekly dosing and why the schedule starts at a low dose) the semaglutide injection overview covers the mechanism clearly. Storage specifics, including what happens if the pen has been left unrefrigerated, are addressed in full on the semaglutide storage guide.
Wegovy is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The NHS medicines page for semaglutide sets out the eligibility criteria and contraindications clearly.
It is not licensed for use in pregnancy, breastfeeding, or for anyone trying to conceive. It is also not licensed for anyone under 18. Certain medical histories (including a personal or family history of medullary thyroid carcinoma, or a history of pancreatitis) require careful discussion with a prescriber before treatment begins. BMI alone does not determine suitability; a proper clinical assessment does.
People sometimes search for the kit as though it were something to source independently. It is not. Semaglutide is a prescription-only medicine, and the only safe route is through a pharmacy that can verify your prescription and source from the licensed UK supply chain. The MHRA has documented large seizures of counterfeit weight-loss pens (some containing entirely the wrong substance) sold through social media and unofficial online sellers. Any seller offering these medicines without requiring a prescription is a red flag, not a bargain. You can verify any online pharmacy on the GPhC register.
Most side effects tied to semaglutide are gastrointestinal: nausea, loose stools, constipation, indigestion, and occasionally vomiting. These are most noticeable after a dose increase, tend to settle within a week or two, and are typically managed by slowing titration, a decision for your prescriber, not something to self-manage. Injection-site reactions (redness, mild swelling, itching) are common and usually brief.
Two things warrant prompt medical attention. First, severe stomach pain that extends to the back, with or without vomiting, may indicate pancreatitis, seek urgent help rather than waiting to see if it passes. The MHRA's Yellow Card scheme is where you report any suspected adverse reaction, and the MHRA issued specific guidance on pancreatitis risk with GLP-1 medicines in January 2026. Second, signs of a serious allergic reaction (facial swelling, difficulty breathing, rapid heartbeat) need emergency care immediately.
The wider side-effect profile, including what the clinical trials found at each dose, is covered on the Wegovy treatment page. If you are weighing up injectable versus non-injectable options, the oral semaglutide page explains what is now available in the UK.
If a clinically assessed, private prescription route is what you are looking for, you can check your eligibility with our prescribers. The consultation is free, and a real clinician reviews your answers, not software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.